No new clinical data or financial surprises — the stock will trade on DA-1726 Phase 1 Part 3 data expectations, not Q1 results. Monitor for Q4 2026 data readout and any partnership announcements for vanoglipel. The $13.7M cash runway into Q4 2026 means a dilutive financing is likely needed before year-end if no partnership materializes.
Price Chart
Executive Summary
MetaVia reported Q1 2026 net loss of $3.8M ($0.79/share) vs $3.7M ($3.93/share) in Q1 2025, with cash of $13.7M expected to fund operations into Q4 2026. The key catalyst is the ongoing Phase 1 Part 3 titration study of DA-1726 (obesity), with first patient dosed in April and data expected in Q4 2026. The filing is a routine quarterly update for a clinical-stage biotech with no new clinical data or financial surprises.
Key Financial Metrics
Key Facts
- Net loss of $3.8M ($0.79/share) for Q1 2026 vs $3.7M ($3.93/share) in Q1 2025
- Cash and cash equivalents of $13.7M as of March 31, 2026, up from $10.2M at year-end 2025
- First patient dosed in Phase 1 Part 3 16-week titration study of DA-1726 (obesity) in April 2026
- Phase 1 Part 3 data readout for DA-1726 expected in Q4 2026
- R&D expenses were $2.1M in Q1 2026 vs $2.3M in Q1 2025
- Weighted average shares outstanding increased to 4,859,567 from 933,109 year-over-year due to January 2026 public offering
- Company expects cash to fund operations into Q4 2026
Financial Impact
Net loss of $3.8M in Q1 2026, essentially flat vs $3.7M in Q1 2025. Cash burn rate remains low at ~$1.3M/month. No revenue reported.
Risk Factors
- Cash runway only into Q4 2026 — likely need for additional dilutive financing
- DA-1726 Phase 1 Part 3 data is binary and not expected until Q4 2026
- Massive dilution from January 2026 offering (shares outstanding increased 5.5x year-over-year)
- No revenue and pre-commercial stage with high clinical development risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-061148 |
| Document: mtva-20260514xex99d2.htm | 0001104659-26-061148 |
| Document: mtva-20260514x8k.htm | 0001104659-26-061148 |
| Document: 0001104659-26-061148-index-headers.html | 0001104659-26-061148 |
| Document: 0001104659-26-061148-index.html | 0001104659-26-061148 |
| Document: 0001104659-26-061148.txt | 0001104659-26-061148 |
| 8-K Data (Synthetic) | 0001104659-26-061148 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 3 | $1.36 | awaiting T+20 | — | $1.16 (−14.74%) |
Oct 13, 2026 14d ago | 8-K | $1.43 | awaiting T+20 | — | $1.16 (−18.91%) |
Sep 9, 2026 6w ago | 8-K | $1.74 $1.46 | ▼ −16.09% | ▼ −18.04% | $1.16 (−33.36%) |
Jul 9, 2026 15w ago | 8-K | $1.73 $1.45 | ▼ −16.18% | ▼ −18.43% | $1.16 (−32.97%) |
Jul 2, 2026 16w ago | 424B5 | $1.48 $1.44 | ▲ +2.70% | ▲ +2.29% | $1.16 (+21.65%) |
Jun 8, 2026 20w ago | 8-K | $1.89 $1.58 | ▼ −16.40% | ▼ −17.85% | $1.16 (−38.65%) |
Jun 8, 2026 20w ago | 8-K | $2.22 $1.51 | ▼ −31.98% | ▼ −33.61% | $1.16 (−47.77%) |
May 27, 2026 21w ago | 8-K | $3.34 $1.53 | ▼ −54.19% | ▼ −52.29% | $1.16 (−65.28%) |
May 18, 2026 23w ago | 8-K | $1.11 $1.65 | ▲ +48.65% | ▲ +47.07% | $1.16 (+4.47%) |
May 14, 2026 23w ago | 8-K | $1.11 $1.71 | ▲ +54.05% | ▲ +51.94% | $1.16 (+4.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers